Columbia Laboratories Reports Results From Phase II Clinical Trial Of Vaginally-administered Lidocaine For Dysmenorrhea

Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced results from its Phase II study of vaginally-administered lidocaine, which the Company is investigating for the prevention and treatment of dysmenorrhea. No treatment currently exists to prevent dysmenorrhea. Seventy women with a history of moderate-to-severe dysmenorrhea participated in this first documented attempt to show prevention of uterine cramping and pain.

More: continued here

Filed under: Pain / Anesthetics on October 3rd, 2008